Abstract
Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 225-231 |
| Number of pages | 7 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 4 |
| Issue number | 3 |
| State | Published - Mar 2006 |
Keywords
- CD20
- Ibritumomab tiuxetan
- NHL
- Radioimmunotherapy
- Tositumomab
ASJC Scopus subject areas
- Hematology
- Oncology